How Supplied
| NDC No. 00186- |
Product No. |
Description | Concentration | Strength | Vial Size/ Fill |
Closure | Pack Size |
Min. Direct Order Qty. |
| 0859-81 | 186085981 | SD
Infusion Bottle |
2 mg/mL | 0.20% | 100 mL | 28 mm | 1 | 12 x 1 |
| 0859-91 | 186085991 | SD
Infusion Bottle |
2 mg/mL | 0.20% | 200 mL | 28 mm | 1 | 12 x 1 |
| 0859-47 | 186085944 | Polyamp DuoFit® Sterile Pak |
2 mg/mL | 0.20% | 10 mL | N/A | 5 | 24 x 5 |
| 0859-57 | 186085954 | Polyamp DuoFit® Sterile Pak |
2 mg/mL | 0.20% | 20 mL | N/A | 5 | 20 x 5 |
| 0863-57 | 186086354 | Polyamp DuoFit® Sterile Pak |
5 mg/mL | 0.50% | 20 mL | N/A | 5 | 20 x 5 |
| 0863-61 | 186086361 | SD Vial | 5 mg/mL | 0.50% | 30 mL | 20 mm | 1 | 50 x 1 |
| 0863-61 | 186086369 | Sterile-Pak SD Vial |
5 mg/mL | 0.50% | 30 mL | 20 mm | 5 | 10 x 5 |
| 0867-57 | 186086754 | Polyamp DuoFit® Sterile Pak |
7.5 mg/mL | 0.75% | 20 mL | N/A | 5 | 20 x 5 |
| 0868-47 | 186086844 | Polyamp DuoFit® Sterile Pak |
10 mg/mL | 1% | 10 mL | N/A | 5 | 24 x 5 |
| 0868-57 | 186086854 | Polyamp DuoFit® Sterile Pak |
10 mg/mL | 1% | 20 mL | N/A | 5 | 20 x 5 |
|
BAR CODED • LATEX FREE • PRESERVATIVE FREE Naropin® is a registered trademark of APP Pharmaceuticals, LLC |
||||||||
is a registered trademark of APP Pharmaceuticals, LLC
|
|
Important Safety Information
Using NAROPIN® beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN® may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
Using NAROPIN® beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN® may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.